Abstract 6598: the Development of a Tumor-Agnostic Liquid Biopsy Assay for Minimal Residual Disease Detection and Monitoring in Cancers

Giancarlo Bonora,Hang Dong,Chao Dai,Binggang Xiang,Billie Gould,Tiantian Zhen,Wei Mo,Xiaohong Wang,Kemin Zhou,Shidong Jia,Shujun Luo,Pan Du
DOI: https://doi.org/10.1158/1538-7445.am2023-6598
IF: 11.2
2023-01-01
Cancer Research
Abstract:Abstract Purpose Non-invasive liquid biopsy (LBx) based assays hold great promise for early cancer diagnosis and disease progression monitoring. Personalized baseline tissue-informed minimal residual disease (MRD) monitoring exhibits a particularly high detection sensitivity in many studies, however, baseline samples (especially tissue biopsies) are often difficult to acquire in a clinical setting, and the personalized panel design and tracking creates operation complexities. Methods We developed PredicineALERTTM, a baseline-agnostic MRD LBx assay that measures methylation and mutational variants associated with cancers. At its core lies the PredicineEPICTM DNA methylation assay with the advantage of low DNA damage and low input amount. Tumor burden is assessed by detecting abnormally methylated DNA fragments with high sensitivity using the Predicine DeepSea bioinformatics analysis pipeline. PredicineALERTTM provides integrated methylation and mutational profiling, as well as copy number variation (CNV) profiling. Results The PredicineALERTTM assay was tested using longitudinal LBx samples (blood, urine, CSF) from patients with mCRPC, CRC, NSCLC, breast, liver, kidney, prostate, and bladder cancers. The PredicineALERTTM assay demonstrates highly-sensitive MRD detection and quatification capability (LOD < 0.01%) using 2.5 - 15ng input cfDNA. It has the ability to identify unique cancer biomarker signatures, and robustly detect MRD ctDNA dynamics during treatment. By leveraging genome-wide fragment-level DNA methylation, PredicineALERTTM measures molecular response and MRD in targeted therapy, immunotherapy and chemotherapy. A strong concordance was observed in the pattern of tumor burden as ascertained by CNV and methylation analyses, respectively. Conclusion We developed PredicinceALERTTM, a baseline agnostic, multidimensional MRD LBx assay without the need for baseline samples and personalized panel design. It integrates DNA methylation, mutation, and copy number changes for detecting MRD from genome-scale data without relying on target selection before library generation. Citation Format: Giancarlo Bonora, Hang Dong, Chao Dai, Binggang Xiang, Billie Gould, Tiantian Zhen, Wei Mo, Xiaohong Wang, Kemin Zhou, Shidong Jia, Shujun Luo, Pan Du. The development of a tumor-agnostic liquid biopsy assay for minimal residual disease detection and monitoring in cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6598.
What problem does this paper attempt to address?